Analyst Confidence Surges for Ocugen Following Clinical Trial Data

Positive results from a mid-stage clinical study have prompted several Wall Street research firms to revise their outlook on Ocugen, with multiple analysts raising their price targets for the biopharmaceutical company’s shares.

Clinical Results Drive Optimism

The renewed analyst interest follows the release of Phase 2 data for Ocugen’s drug candidate OCU410, which is being evaluated for geographic atrophy, an advanced form of dry age-related macular degeneration. The ArMaDa study reported that after twelve months, patients in the high-dose cohort showed a 16% reduction in lesion size. An even more significant reduction of 31% was observed in the medium-dose group. The trial reported no serious adverse events or study discontinuations among the 39 patients evaluated.

Revised Price Targets and Ratings

In direct response to these findings, HC Wainwright increased its price target from $7 to $10 per share, maintaining a Buy rating on the stock. Analyst Swayampakula Ramakanth noted the efficacy data appears comparable to already approved therapies. He further highlighted that OCU410’s potential as a one-time treatment could become a major differentiator against competing options, provided Phase 3 trials yield similar outcomes.

This move adds to a wave of recent analyst coverage. Canaccord Genuity initiated coverage on March 17 with a Buy rating and a $12 price target. Oppenheimer followed on March 11, assigning an Outperform rating with a $10 target. According to data from MarketBeat, the consensus rating for Ocugen stands at “Moderate Buy,” with an average price target of $9.75. This implies substantial potential upside from the current trading level of approximately €1.70.

Should investors sell immediately? Or is it worth buying Ocugen?

Strengthened Financial Position and Pipeline Momentum

Concurrent with its clinical progress, Ocugen has bolstered its balance sheet. In March, an institutional investor exercised warrants from a direct placement completed in August 2025, providing the company with $15 million in proceeds. Management believes this liquidity extends its financial runway into the first quarter of 2027 without the need for additional fundraising.

The company’s development pipeline features several approaching milestones. Ocugen plans to initiate the Phase 3 trial for OCU410 in the third quarter of 2026, subject to regulatory alignment. This study is designed to enroll approximately 300 patients and is projected to have over 95% statistical power.

Meanwhile, enrollment in the Phase 2/3 GARDian3 trial for OCU410ST is progressing ahead of schedule, with interim data also anticipated in Q3 2026. For its OCU400 program targeting retinitis pigmentosa, the company is aiming to submit a rolling Biologics License Application (BLA) before the end of 2026.